Introduction
============

Malignancy is an important non-communicable global disease estimated to be causing 9 million deaths annually [@B1]. Recent advance in anti-cancer treatment has gradually improved the overall survival of patients with metastatic cancer [@B2]-[@B4]. Despite the improvement in cancer treatment and patient survival, facing and treating critical illness such as sepsis, however, in cancer patients remains inevitable in most patients\' clinical course.

Admitting to intensive care unit (ICU) is an aggressive approach for treating critical illness; however, ICU admission also means less time for family companion and invasive procedures in ICU lead to suffering and psychological trauma to patients and their caregivers [@B5], [@B6]. ICU admission was once considered unsuitable and futile for patients with cancer diagnosis, either from a physician\'s or patient\'s perspective [@B7], [@B8]. In a multi-center study in France, the presence of metastatic cancer was associated with nearly 6-fold increase in ICU refusal by physician, patient or family [@B7]. Furthermore, one ICU admission for cancer patient may deprive the opportunity of another patient to be admitted to ICU in case of limited critical care resource.

As more data are accumulating that the survival of critical cancer patients are improving, the attitude toward ICU admission for cancer patients may have gradually changed [@B9], [@B10]. Most studies addressing cancer patients and critical care utilization, however, focused only on short term (in-hospital) outcome, were in lack of population-based data, and did not include a comparison group in which septic shock was managed outside ICU [@B9], [@B11].

There is general expectation of helping individual patient survive critical events and thus lead to long-term survival for physicians with an optimistic and aggressive attitude toward ICU admission [@B12]-[@B15]. This expectation, or hypothesis, however, has not been explored before.

Material and Methods
====================

Participants and setting
------------------------

This study was conducted with linkage of Taiwan National Health Insurance (NHI) claims data, mortality data from the Department of Statistics, and Taiwan Cancer Registry. The NHI claims data in Taiwan has been previously described [@B16], [@B17].

Taiwan Cancer Registry is a prospective population-based cancer data collection platform launched since 1979. In Taiwan Cancer Registry, TNM staging according to American Joint Committee on Cancer staging edition at initial diagnosis is available in the long-form database, which includes more than 90% of all cancer patients in Taiwan [@B18]. Through linkage between Taiwan Cancer Registry, NHI claims data, and mortality data, researchers are able to follow cancer patients from initial diagnosis, treatment course to the end of life.

We identified incident stage IV cancer (at initial diagnosis) patients in Taiwan Cancer Registry during 2009-2013 [@B18]. The enrolled patients were divided into two groups, namely with/without admission to ICU during their index hospitalization for septic shock.

Inclusion and Exclusion Criteria
--------------------------------

Patients were included if they had their first episode of septic shock after diagnosis of stage IV cancer. Patients were excluded if (1) had history of admission to ICU before their first septic shock episode, (2) had history of inotropic agents use before their first septic shock episode, (3) age \< 20 years at cancer diagnosis.

Definition and Data Collection
------------------------------

Though ICU admission could be identified during a specific hospitalization, definite date of ICU admission during that hospitalization was not readily available in the NHI data. Cohort entry date was the date of admission of the index hospitalization for septic shock.

The diagnosis of stage IV cancer was ascertained through Taiwan Cancer Registry. Patients were defined to have septic shock if they fulfilled both the following criteria 1. The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes for both a bacterial or fungal infectious process and a diagnosis of acute organ dysfunction or a ICD-9-CM code of severe sepsis (995.92) or septic shock (785.52). 2. Use of any inotropic agents, including dopamine, norepinephrine, epinephrine and vasopressin [@B19], [@B20].

Cancer-type was divided into 14 categories, including oral cavity, oropharynx, hypopharynx, esophagus, stomach, colon, rectum, liver, lung, breast, uterine cervix, prostate, bladder and other cancer. The designation of International Classification of Diseases for Oncology, 3rd edition (ICD-O-3) codes for each cancer type was illustrated in**Table [S1](#SM0){ref-type="supplementary-material"}**. We used the Deyo version of the Charlson comorbidity index (CCI) for assessing patients\' underlying medical condition and calculated the CCI according to medical claims records in NHI claims database one year before cohort entry [@B21]. Socioeconomic status was determined by income reported for premium calculation, which was divided into low income (receiving government subsidies due to being below the lowest living index and being exempted from NHI premiums and copayment), ≦Q1, Q1 to Q3 and ≧Q3 as previously published [@B22], [@B23]. The codes for variable definitions used in this study were summarized in**Table [S2](#SM0){ref-type="supplementary-material"}.**

Statistical analysis
--------------------

Proportions or means were used to describe the demographic and clinical characteristics of the patients. Standardized difference was used to compare between continuous variables and categorical variables at baseline before the index hospitalization. The propensity score (PS) for the probability of being admitted to ICU was derived using logistic regression model including potential confounders such as age, sex, socioeconomic status, cancer type, use of positron emission tomography (PET), CCI, antineoplastic therapy, interval between cancer diagnosis and the occurrence of septic shock, and inotropic agents used.

Primary outcome was overall survival, which was defined as the interval between date of admission of the index hospitalization and date of death. Secondary outcomes included in-hospital mortality and long-term survival after discharge from the index hospitalization which was defined as the interval between date of discharge and date of death. Participants were censored if they were still alive at end of the study period (2014-12-31).

For analysis of overall survival, we included all stage IV cancer patients experiencing their first septic shock episode after the initial diagnosis. The proportional hazards regression model stratified on quintiles of the PS was applied to compare the overall survival between patients with/without ICU admission as the PS-stratified analysis. As for the PS-matched analysis, a 1:1 PS-matched population was created according to caliper measurements of \< 0.2 standard deviations of the logit of the PS for stage IV cancer patients admitted and not admitted to the ICU. And the proportional hazards regression model was applied to estimate the relative hazard of death between patients with/without ICU admission among the PS-matched population.

Concerning in-hospital mortality, the PS-stratified analysis was conducted by means of the logistic regression model to estimate the odds ratio (OR) within each of the PS quintile stratum with the pooled OR across 5 PS strata obtained by the Mantel-Haenszel estimate. Besides, the logistic regression model was also used among the PS-matched population for analysis of in-hospital mortality.

For long-term survival after discharge, we included only patients who survived to discharge from the index hospitalization with another set of PS created accordingly.

A sensitivity analysis was performed with exclusion of patients who died within 7 days after hospital discharge for evaluation of long-term survival after discharge. Subgroup analyses were performed with stratification by specific cancer types. All data analyses were performed using SAS version 9.4 (SAS Institute Inc, Cary, NC, USA). A P \< 0.05 on a two-sided test or a standardized difference \> 0.1 was considered statistically significant.

Results
=======

A total of 11,825 stage IV cancer patients fulfilled the inclusion criteria. The patient identification process is illustrated in **Fig. [1](#F1){ref-type="fig"}**. Clinical characteristics of stage IV cancer patients experiencing septic shock are illustrated in**Table [1](#T1){ref-type="table"}**. Among them, 6,089 (51.5%) patients were admitted to ICU during the index hospitalization while 5,736 (48.5%) patients were not admitted to ICU during the index hospitalization. The mean age was 66 and there was a male preponderance (M/F: 8,465/3,360). The most common cancer type was lung cancer (n=4,097, 34.6%), followed by liver cancer (n=1,046, 8.8%) and oral cancer (n=1,046, 8.8%). More than half (n=6,313, 53.4%) patients received chemotherapy before this index hospitalization. Those admitted to ICU were more likely to be male. Those admitted to ICU were more likely to have oral cavity cancer and less likely to have liver cancer. Patients with ICU admission were more likely to receive PET and various vasopressors than those not admitted to ICU. The crude in-hospital mortality rate among the overall population was 69% (68.7% in the ICU admission group versus 70% in the ICU no admission group). The medical utilizations including artificial organ support, cardiopulmonary resuscitation (CPR), and palliative care in the study population were summarized in **Table [S3](#SM0){ref-type="supplementary-material"}**.

A 1:1 PS-matched cohort of 7,186 patients for analyzing overall survival and in-hospital mortality were created. After matching, the baseline characteristics were similar between two groups **(Table [1](#T1){ref-type="table"}).**

ICU admission was associated with better overall survival in both PS-stratified analysis (pooled HR: 0.78, 95% CI: 0.74-0.81, **Table [2](#T2){ref-type="table"}**) and PS-matched analysis (adjusted HR: 0.76, 95% CI: 0.72-0.79). In addition, ICU admission was associated with a lower risk of in-hospital mortality in both PS-stratified analysis (pooled OR: 0.69, 95% CI: 0.63-0.75) and PS-matched analysis (OR: 0.61, 95% CI: 0.55-0.68,**Table [S4](#SM0){ref-type="supplementary-material"}**).

A total of 3,626 (30.7%) patients survived to hospital discharge. The most common cancer type among hospital survivors were lung cancer (n=996, 27.5%) and oral cancer (n=633, 17.5%). Among the 3,626 hospital survivors, 1,908 (52.6%) patients have been admitted to ICU during hospitalization **(Table [3](#T3){ref-type="table"}).** The medical utilizations including artificial organ support, cardiopulmonary resuscitation and palliative care in the study population who survived to discharge from the index hospitalization were summarized in **Table [S5](#SM0){ref-type="supplementary-material"}**.

Another 1:1 PS-matched cohort of 2,194 patients were created among survivors of the index hospitalization. After matching, all baseline characteristics became balanced between groups except for oral cancer (oral cancer was more common among those not admitted to ICU compared with those admitted to ICU, 15.0% vs 10.9%, standardized difference = 0.122) **(Table [3](#T3){ref-type="table"})**. In PS-stratified analysis for long-term survival after discharge among hospital survivors, ICU admission was associated with improved long-term survival (pooled HR: 0.73, 95% CI: 0.68-0.80) **(Table [S6](#SM0){ref-type="supplementary-material"})**. Also ICU admission was associated with better long-term survival after discharge (HR: 0.77, 95% CI: 0.70-0.85) in PS-matched analysis.

Forest plots regarding association between overall survival and ICU admission stratified by different cancer types are illustrated in **Fig. [2](#F2){ref-type="fig"}**. A sensitivity analysis was performed for analysis of long-term survival after discharge among hospital survivors by excluding patients who died within 7 days after discharge from the index hospitalization. The results of stratified PS analysis were similar to our original analysis and all indicated an association between ICU admission and better long-term survival after discharge. ICU admission was associated with better long-term survival after discharge (HR: 0.85, 95% CI: 0.76-0.94) in PS-matched analysis. The detailed results of sensitivity analysis is shown in**Table [S7](#SM0){ref-type="supplementary-material"} and Table [S8](#SM0){ref-type="supplementary-material"}**.

Discussion
==========

In our study, by identifying a large population-based cohort we found that admission to ICU for septic shock was associated with better overall survival, lower in-hospital mortality and better long-term survival after discharge among stage IV cancer patients. 70% of stage IV cancer patients with septic shock, however, failed to survive until discharge.

One major strength of our study was that we investigated the impact of ICU admission on overall survival of cancer patients and included a comparison group without ICU admission, which was not commonly assessed in previous studies [@B9], [@B10], [@B24], [@B25]. In our analysis of hospital survivors of cancer patients from septic shock, an improved long-term survival after discharge was observed among those who were admitted to ICU, indicating that benefit of admitting to ICU extended beyond hospitalization. Aggressive treatment and even implementation of artificial organ during ICU care **(Table [S3](#SM0){ref-type="supplementary-material"} and Table [S5](#SM0){ref-type="supplementary-material"})** may not only improve short-term (in-hospital) survival but also help preserve organ function and thus lead to better long-term survival. For instance, in severe sepsis patients with respiratory failure, mechanical ventilation could improve gas exchange, decrease work of breathing, avoid lung damage and could be life-saving [@B26]. Protocolized and detailed sepsis bundle management is less likely to be implemented outside ICU setting where higher staff to patient ratio is equipped [@B27]. Performing and adhering to sepsis bundle improve patient survival and decrease mortality [@B28]. Furthermore, new insight into artificial organ support for organ protection including lung protective strategy and permissive hypercapnia may influence inflammatory mediators and preserve end-organ function [@B29]. The abovementioned mechanisms may together contribute to a better outcome in cancer patients with septic shock.

One may question that the decision to admit stage IV cancer patients to ICU may not be at random and may be confounded by indication. For instance, physicians may choose those who were likely to survive the event and had better anticipated anti-cancer treatment to be admitted to ICU. Indeed, not all sepsis patients were managed in the ICU [@B30]. Sepsis patients managed outside ICU, were found to have a lower disease severity compared with those managed in ICU [@B28]. The high percentage of patients receiving mechanical ventilation (76%) in ICU in this study also indicated higher disease severity since respiratory failure is an indicator of disease severity [@B31]. Furthermore, the costs of ICU admission are relatively low in Taiwan and there are no restrictions on admitting cancer patients to ICU by Taiwan NHI [@B32], [@B33]. The decision of ICU admission, therefore, was most likely to be based on patients\' as well as caregivers\' aggressiveness (eg, deciding to receive endotracheal intubation for respiratory failure). In our study more patients admitted to ICU received CPR and more patients not admitted to ICU received palliative care **(Table [S3](#SM0){ref-type="supplementary-material"} and Table [S4](#SM0){ref-type="supplementary-material"})**. Since ICU admission was considered an aggressive attitude toward treatment, our study was in concordance with this concept [@B25].

The in-hospital mortality rate of septic shock patients is estimated to range from 18% to 50% [@B34], [@B35]. Though our study did not include a control group of septic shock patients without cancer, the in-hospital mortality rate (around 70%) in our study seemed to be higher compared with previous reports [@B34], [@B35]. This finding may not be surprising since we selected a group of stage IV cancer patients who were considered to have a dismal prognosis. This high in-hospital mortality rate also raises concerns of critical care service rationing and issue of equity [@B36], [@B37]. When physicians decide to admit cancer patients to ICU, it should be kept in mind that the admitted cancer patients should be likely to benefit from ICU service; otherwise this may do harm to other patients who also need critical care service.

Our study also has limitations. First, though we have implemented PS matching to control for potential confounders and included important variables including cancer-type, use of PET in staging (which was known as an indicator of stage migration and better prognostic factor) [@B38] and previous anti-cancer treatment in the PS, we still cannot exclude the possibility of uncontrolled confounding, which could not be ascertained from the insurance claims. Second, we have no data on quality of life among critical illness survivors. Potential deterioration in quality of life even after surviving critical illness, therefore, should be informed to family and patient [@B39]. Third, we were unable to recruit another independent validation cohort in Taiwan since NHI is a single-payer health system that provides universal coverage for medical services in Taiwan [@B40]. Further studies from different healthcare systems may be warranted to further validate our findings.

Conclusions
===========

In conclusion, we found that utilization of ICU during septic shock in stage IV cancer patients may be associated with improved survival. Nonetheless, the in-hospital mortality rate remained high even after aggressive treatment under ICU setting. Our findings could be informative to physicians, cancer patients, and their relatives. Future studies should be aimed at providing long-term quality of life data among cancer patients surviving septic shock.
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###### 

Clinical characteristics of stage IV cancer patients with septic shock.

                                                                                     Before PS Matching   After PS Matching                                                                     
  ---------------------------------------------------------------------------------- -------------------- ------------------- ------------- --------- ------------- ------------- ------------- -----------
  **Age** (mean ±SD)                                                                 66.1±13.9            66.8±14.1           65.5±13.7     0.088     66.3±14.0     66.0±14.2     66.6±13.7     0.041
  **Gender**                                                                                                                                                                                    
  Male                                                                               8465(71.6)           3919 (68.3)         4546 (74.7)   0.141     5165(71.9)    2578 (71.8)   2587 (72.0)   0.006
  Female                                                                             3360(28.4)           1817 (31.7)         1543 (25.3)             2021(28.1)    1015 (28.2)   1006 (28.0)   
  **Socioeconomic status**                                                                                                                                                                      
  Low income                                                                         291(2.5)             153 (2.7)           138 (2.3)     0.026     187(2.6)      95 (2.6)      92 (2.6)      0.005
  ≦Q1                                                                                4089(34.6)           2016 (35.1)         2073 (34.0)   0.023     2434(33.9)    1201 (33.4)   1233 (34.3)   0.019
  Q1-Q3                                                                              4938(41.8)           2355 (41.1)         2583 (42.4)   0.028     3058(42.6)    1527 (42.5)   1531 (42.6)   0.002
  \>Q3                                                                               2507(21.2)           1212 (21.1)         1295 (21.3)   0.003     1507(21.0)    770 (21.4)    737 (20.5)    0.023
  **Cancer type**                                                                                                                                                                               
  Oral Cavity                                                                        1046(8.8)            323 (5.6)           723 (11.9)    0.222     626(8.7)      321 (8.9)     305 (8.5)     0.016
  Oropharynx                                                                         534(4.5)             231 (4.0)           303 (5.0)     0.046     331(4.6)      160 (4.5)     171 (4.8)     0.015
  Hypopharynx                                                                        440(3.7)             186 (3.2)           254 (4.2)     0.049     261(3.6)      133 (3.7)     128 (3.6)     0.007
  Esophagus                                                                          404(3.4)             164 (2.9)           240 (3.9)     0.060     265(3.7)      137 (3.8)     128 (3.6)     0.013
  Stomach                                                                            749(6.3)             425 (7.4)           324 (5.3)     0.086     454(6.3)      234 (6.5)     220 (6.1)     0.016
  Colon                                                                              878(7.4)             420 (7.3)           458 (7.5)     0.008     556(7.7)      280 (7.8)     276 (7.7)     0.004
  Rectum                                                                             475(4.0)             221 (3.9)           254 (4.2)     0.016     299(4.2)      149 (4.1)     150 (4.2)     0.001
  Liver                                                                              1046(8.8)            615 (10.7)          431 (7.1)     0.128     603(8.4)      309 (8.6)     294 (8.2)     0.015
  Lung                                                                               4097(34.6)           2111 (36.8)         1986 (32.6)   0.088     2467(34.3)    1218 (33.9)   1249 (34.8)   0.018
  Breast                                                                             266(2.2)             142 (2.5)           124 (2.0)     0.030     152(2.1)      77 (2.1)      75 (2.1)      0.004
  Cervix                                                                             160(1.4)             98 (1.7)            62 (1.0)      0.060     92(1.3)       47 (1.3)      45 (1.3)      0.005
  Prostate                                                                           605(5.1)             272 (4.7)           333 (5.5)     0.033     389(5.4)      187 (5.2)     202 (5.6)     0.018
  Bladder                                                                            169(1.4)             76 (1.3)            93 (1.5)      0.017     107(1.5)      50 (1.4)      57 (1.6)      0.016
  Other                                                                              956(8.1)             452 (7.9)           504 (8.3)     0.015     584(8.1)      291 (8.1)     293 (8.2)     0.002
  **Use of PET**                                                                     1175(9.9)            476 (8.3)           699 (11.5)    0.107     702(9.8)      337 (9.4)     365 (10.2)    0.026
  **CCI** (mean ±SD)                                                                 9.27±1.45            9.26±1.42           9.27±1.47     0.003     9.28±1.47     9.27±1.44     9.30±1.49     0.017
  **Anti-cancer therapy**                                                                                                                                                                       
  Chemotherapy                                                                       6313(53.4)           3042 (53.0)         3271 (53.7)   0.014     3845(53.5)    1948 (54.2)   1897 (52.8)   0.028
  Radiotherapy                                                                       3788(32.0)           1770 (30.9)         2018 (33.1)   0.049     2317(32.2)    1167 (32.5)   1150 (32.0)   0.010
  TKI                                                                                1163(9.8)            603 (10.5)          560 (9.2)     0.044     709(9.9)      361 (10.0)    348 (9.7)     0.012
  Antibody                                                                           747(6.3)             368 (6.4)           379 (6.2)     0.008     457(6.4)      228 (6.3)     229 (6.4)     0.001
  Interval Between Index Hospitalization Admission and Cancer Diagnosis (mean ±SD)   232.7±296.5          241.6±303.8         224.4±289.2   0.058     234.2±294.8   233.8±289.4   234.7±300.1   0.003
  **Inotropic Agents**                                                                                                                                                                          
  Epinephrine                                                                        6,650 (56.2)         3080 (53.7)         3570 (58.6)   0.100     3673(51.1)    1845 (51.3)   1828 (50.9)   0.009
  Dopamine                                                                           6038(51.1)           2545 (44.4)         3493 (57.4)   0.262     3384(47.1)    1687 (47.0)   1697 (47.2)   0.006
  Norepinephrine                                                                     5319(45.0)           1595 (27.8)         3724 (61.2)   0.712     2948(41.0)    1464 (40.7)   1484 (41.3)   0.011
  Vasopressin                                                                        281(2.4)             17 (0.3)            264 (4.3)     0.271     39(0.5)       17 (0.5)      22 (0.6)      0.019
  **In-hospital mortality**                                                          8199(69.3)           4018 (70.0)         4181 (68.7)   0.103\*   4863(67.7)    2610 (72.6)   2253 (62.7)   \<0.001\*

Abbreviations: CCI, Charlson comorbidity index; ICU, intensive care unit; PET, positron emission tomography; PS, propensity score; Q1, first quartile; Q3, third quartile; SD, standard deviation; STD, standardized difference; TKI, tyrosine kinase inhibitor.

\*p value.

###### 

Association between ICU admission and overall survival evaluated by proportional hazards model with stratification on quintiles of the propensity score.

  Quintiles of PS   Patients without admission to ICU   Patients with admission to ICU                                    
  ----------------- ----------------------------------- -------------------------------- -------- ------- ------ -------- -----------------
  1                 0.018                               339                              18865    0.012   1949   161155   0.78(0.70-0.88)
  2                 0.009                               714                              80916    0.004   1405   364629   0.67(0.62-0.74)
  3                 0.012                               1217                             103436   0.007   1010   136080   0.78(0.72-0.85)
  4                 0.008                               1486                             178014   0.005   740    139192   0.79(0.72-0.86)
  5                 0.010                               1708                             177186   0.008   532    63873    0.90(0.81-0.99)
  Pooled                                                                                                                  0.78(0.74-0.81)

Abbreviations: CI, confidence interval; HR, hazard ratio; ICU, intensive care unit; PS, propensity score

###### 

Clinical characteristics of stage IV cancer patients with septic shock who survived to discharge.

                                                                      Before PS Matching                 After PS Matching                                                     
  ------------------------------------------------------------------- -------------------- ------------- ------------------- ------- ------------- ------------- ------------- -------
  **Age (mean ±SD)**                                                  64.1±13.7            64.4±13.9     63.7±13.5           0.050   64.7±13.8     64.4±14.0     65.0±14.0     0.038
  **Gender**                                                                                                                                                                   
  Male                                                                2661(73.4)           1189(69.2)    1472(77.1)          0.180   1590 (72.5)   800(72.9)     790(72.0)     0.020
  Female                                                              965(26.6)            529(30.8)     436(22.9)                   604 (27.5)    297(27.1)     307(28.0)     
  **Socioeconomic status**                                                                                                                                                     
  Low income                                                          94(2.6)              58(3.4)       36(1.9)             0.093   60 (2.7)      30(2.7)       30(2.7)       0.000
  ≦Q1                                                                 1130(31.2)           532(31.0)     598(31.3)           0.008   678 (30.9)    337(30.7)     341(31.1)     0.008
  Q1-Q3                                                               1659(45.8)           771(44.9)     888(46.5)           0.033   1017 (46.4)   507(46.2)     510(46.5)     0.005
  \>Q3                                                                743(20.5)            357(20.8)     386(20.2)           0.014   439 (20.0)    223(20.3)     216(19.7)     0.016
  **Cancer type**                                                                                                                                                              
  Oral Cavity                                                         633(17.5)            169(9.8)      464(24.3)           0.394   285 (13.0)    165(15.0)     120(10.9)     0.122
  Oropharynx                                                          241(6.6)             110(6.4)      131(6.9)            0.019   155 (7.1)     78(7.1)       77(7.0)       0.004
  Hypopharynx                                                         211(5.8)             110(6.4)      101(5.3)            0.047   137 (6.2)     68(6.2)       69(6.3)       0.004
  Esophagus                                                           101(2.8)             36(2.1)       65(3.4)             0.08    70 (3.2)      33(3.0)       37(3.4)       0.021
  Stomach                                                             153(4.2)             82(4.8)       71(3.7)             0.052   103 (4.7)     51(4.6)       52(4.7)       0.004
  Colon                                                               255(7.0)             110(6.4)      145(7.6)            0.047   166 (7.6)     83(7.6)       83(7.6)       0.000
  Rectum                                                              146(4.0)             61(3.6)       85(4.5)             0.046   111 (5.1)     54(4.9)       57(5.2)       0.012
  Liver                                                               213(5.9)             125(7.3)      88(4.6)             0.113   147 (6.7)     71(6.5)       76(6.9)       0.018
  Lung                                                                996(27.5)            572(33.3)     424(22.2)           0.249   587 (26.8)    281(25.6)     306(27.9)     0.051
  Breast                                                              89(2.5)              49(2.9)       40(2.1)             0.049   52 (2.4)      24(2.2)       28(2.6)       0.024
  Cervix                                                              55(1.5)              33(1.9)       22(1.2)             0.062   31 (1.4)      15(1.4)       16(1.5)       0.008
  Prostate                                                            189(5.2)             91(5.3)       98(5.1)             0.007   131 (6.0)     64(5.8)       67(6.1)       0.012
  Bladder                                                             50(1.4)              20(1.2)       30(1.6)             0.035   34 (1.5)      18(1.6)       16(1.5)       0.015
  Other                                                               294(8.1)             150(8.7)      144(7.5)            0.043   185 (8.4)     92(8.4)       93(8.5)       0.003
  **Use of PET**                                                      365(10.1)            149(8.7)      216(11.3)           0.088   215 (9.8)     108(9.8)      107(9.8)      0.003
  **CCI**                                                             9.1±1.4              9.1±1.4       9.1±1.4             0.020   9.1±1.4       9.1±1.4       9.2±2.0       0.044
  **Anti-cancer therapy**                                                                                                                                                      
  Chemotherapy                                                        1668(46.0)           807(47.0)     861(45.1)           0.037   1103 (50.3)   551(50.2)     552(50.3)     0.002
  Radiotherapy                                                        1018(28.1)           493(28.7)     525(27.5)           0.029   656 (29.9)    330(30.1)     326(29.7)     0.008
  TKI                                                                 227(6.3)             119(6.9)      108(5.7)            0.052   151 (6.9)     78(7.1)       73(6.7)       0.018
  Antibody                                                            224(6.2)             104(6.1)      120(6.3)            0.010   139 (6.3)     70(6.4)       69(6.3)       0.004
  Interval Between Admission to ICU and Cancer Diagnosis (mean ±SD)   206.2±298. 8         217.1±311.7   196.3±286.4         0.069   222.3±304.0   216.2±293.7   228.4±313.8   0.040
  **Inotropic Agents**                                                                                                                                                         
  Epinephrine                                                         1982(54.7)           1020(59.4)    962(50.4)           0.181   1024 (46.7)   519(47.3)     505(46.0)     0.026
  Dopamine                                                            1367(37.7)           534(31.1)     833(43.7)           0.262   879 (40.1)    423(38.6)     456(41.6)     0.061
  Norepinephrine                                                      1136(31.3)           308(17.9)     828(43.4)           0.575   629 (28.7)    300(27.3)     329(30.0)     0.058
  Vasopressin                                                         38(1.0)              9(0.5)        29(1.5)             0.099   13 (0.6)      7(0.6)        6(0.5)        0.012

Abbreviations: CCI, Charlson comorbidity index; ICU, intensive care unit; PET, positron emission tomography; PS, propensity score; Q1, first quartile; Q3, third quartile; SD, standard deviation; STD, standardized difference; TKI, tyrosine kinase inhibitor.
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